Products
Companies
News
About
About
FAQ
Contact
Contact
Newsletter
×
Subscribe to our monthly newsletter
Subscribe
Products
QP-Prostate
QP-Prostate
Quibim
QP-Prostate is a medical imaging software that supports radiologists in the detection of clinically significant prostate cancer. It provides automatic lesion detection and risk scoring (High and Moderate) for the presence of csPCa. It also provides quantitative information, including prostate volume and dimensions, Apparent Diffusion Coefficient (ADC) map, computed high b-value and perfusion metrics (K trans, K ep, V e).
The information is compiled by the radiologist in a prostate structured report template based on PI-RADS guidelines.
Information source:
Vendor
Last updated:
January 30, 2024
General Information
Technical Specifications
Regulatory
Market
Evidence
General Information
General
Product name
QP-Prostate
Company
Quibim
Subspeciality
Abdomen
Modality
MR
Disease targeted
Prostate Cancer
Key-features
Lesion detection, prostate segmentation, PI-RADS 2.1 structured report
Suggested use
During: perception aid (prompting all abnormalities/results/heatmaps)
Technical Specifications
Data characteristics
Population
Male adult population. Exclusion: patients with endorectal coil, radical prostatectomy or hip prosthesis.
Input
T2w, DWI sequence, DCE (not needed for lesion detection)
Input format
DICOM
Output
Lesion detection overlay, prostate segmentation overlay, quantitative information (ADC, high b-value, Ktrans, Kep, Ve), structured report based on PI-RADS 2.1
Output format
DICOM SC
Technology
Integration
Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform, Stand-alone webbased
Deployment
Cloud-based
Trigger for analysis
Automatically, right after the image acquisition
Processing time
1 - 10 minutes
Regulatory
Certification
CE
Certified, Class IIb
, MDR
FDA
510(k) cleared , Class II
Intended Use Statements
Intended use (according to CE)
Medical imaging processing application intended for image processing and analysis of prostate MRI indicated for adult patients
Market
Market presence
On market since
CE/UKCA 10-2022. 510(k) clearance since 12-2020.
Distribution channels
Philips Healthcare
Countries present (clinical, non-research use)
10
Paying clinical customers (institutes)
Research/test users (institutes)
Pricing
Pricing model
Subscription
Based on
Number of analyses
Evidence
Evidence
Peer reviewed papers on performance
Automated prostate multi-regional segmentation in magnetic resonance using fully convolutional neural networks
(read)
Non-peer reviewed papers on performance
Other relevant papers
Automatic individual arterial input functions calculated from PCA outperform manual and population-averaged approaches for the pharmacokinetic modeling of DCE-MR images
(read)